Topic: Chutes and Ladders
New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.
Jonathan Symonds, with plenty of experience in major life science deals, could be a strong fit for GSK as it looks to separate consumer health with pharma.
Back in May, new Gilead CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick.
Ex-Shire CFO Jeff Poulton has landed at Alnylam. He'll replace current CFO Manmeet Soni, "arguably the best CFO in mid-cap biotech," one analyst said.
Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.
Novartis lost pharma chief Paul Hudson to the CEO job at Sanofi. But his replacement's ready: company insider and Celgene veteran Marie-France Tschudin.
Sanofi CEO Olivier Brandicourt took the reins at a tough time for the drugmaker. Now, he's handing those reins to Novartis pharma chief Paul Hudson.
AstraZeneca's Leif Johansson has put in seven years as chairman, and the company's starting to scout for a potential successor, Sky News reports.
Bristol-Myers Squibb is losing another key commercial cog, and this time Gilead is the culprit.
Paul McKenzie has become COO of CSL Behring, having left Biogen as it struggles following the failure of its late-stage Alzheimer’s candidate.